Sepsivac is a drug developed by Cadila Pharmaceuticals to treat gram-negativesepsis. The active ingredient is heat-killed Mycobacterium w, a non-pathogenic strain of Mycobacterium. As an immunomodulatory, it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis. Sepsivac is a drug developed by CSIR and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme.[1] In many cases, Sepsivac has proven to provide effective care and relief to COVID patients.[2]
In patients with sepsis, in response to an infection, a lot of pro-inflammatory and anti-inflammatorycytokines are generated in the body. However, some of the cytokines also cause inflammation in the organs of the body, which might be harmful. Immunomodulator drugs such as Sepsivac regulate this host immune response.[4] Sepsivac is found to be safe in patients with no systematic side-effects. It can be used in combination with other treatments to manage a patient in critical care setting.[5]
Sepsivac and COVIDedit
Scientists at CSIR found similarities between the clinical characteristics of patients with gram-negative sepsis and COVID-19. In association with Cadila Pharmaceuticals, the researchers are now working on initiating a randomised, blinded, controlled clinical trial to evaluate Sepsivac's efficacy to reduce mortality in critically ill COVID-19 patients.[1] The repurposed drug will boost the immunity of the body and limit the spread of COVID-19 and increase the recovery rate.[6] The clinical trials will be conducted at national hospitals including PGIMER Chandigarh, AIIMS New Delhi, and AIIMS, Bhopal.[7]
Referencesedit
^ abSingh J (22 April 2020). "Indian Researchers Plan Clinical Trials of Sepsis Drug Against New Coronavirus". The Wire Science. Retrieved 28 April 2020.
^Chakrabarti, Ganguly (29 April 2021). "Is there a way to tame the Covid virus?". @businessline. Retrieved 30 April 2021.
^"Sepsivac – A First-In-The-World Innovation for Sepsis Management". Cadila Pharma.
^Koshy J (2020-04-21). "Coronavirus | Drug for sepsis to be tested for COVID-19". The Hindu. ISSN 0971-751X. Retrieved 28 April 2020.
^Paliath S (22 April 2020). "Gram-negative sepsis drug to be trialled for treating critically-ill COVID-19 patients". www.indiaspend.com. Retrieved 28 April 2020.
^"Sepsivac to be tested for COVID-19 treatment". The New Indian Express. 24 April 2020. Retrieved 28 April 2020.
^Ray K (23 April 2020). "50-yr-old bacteria drug makes a comeback in fight against coronavirus". Deccan Herald. Retrieved 28 April 2020.
This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it.
sepsivac, drug, developed, cadila, pharmaceuticals, treat, gram, negative, sepsis, active, ingredient, heat, killed, mycobacterium, pathogenic, strain, mycobacterium, immunomodulatory, modulates, immune, system, body, hence, significantly, reduces, mortality, . Sepsivac is a drug developed by Cadila Pharmaceuticals to treat gram negative sepsis The active ingredient is heat killed Mycobacterium w a non pathogenic strain of Mycobacterium As an immunomodulatory it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis Sepsivac is a drug developed by CSIR and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative NMITLI programme 1 In many cases Sepsivac has proven to provide effective care and relief to COVID patients 2 SepsivacClinical dataOther namesMycobacterium w heat killed IdentifiersCAS Number2781058 36 2Sepsivac is approved by the Drug Controller General of India DCGI for treatment of sepsis or septic shock 3 better source needed Contents 1 Mechanism 2 Sepsivac and COVID 3 ReferencesMechanism editIn patients with sepsis in response to an infection a lot of pro inflammatory and anti inflammatory cytokines are generated in the body However some of the cytokines also cause inflammation in the organs of the body which might be harmful Immunomodulator drugs such as Sepsivac regulate this host immune response 4 Sepsivac is found to be safe in patients with no systematic side effects It can be used in combination with other treatments to manage a patient in critical care setting 5 Sepsivac and COVID editScientists at CSIR found similarities between the clinical characteristics of patients with gram negative sepsis and COVID 19 In association with Cadila Pharmaceuticals the researchers are now working on initiating a randomised blinded controlled clinical trial to evaluate Sepsivac s efficacy to reduce mortality in critically ill COVID 19 patients 1 The repurposed drug will boost the immunity of the body and limit the spread of COVID 19 and increase the recovery rate 6 The clinical trials will be conducted at national hospitals including PGIMER Chandigarh AIIMS New Delhi and AIIMS Bhopal 7 References edit a b Singh J 22 April 2020 Indian Researchers Plan Clinical Trials of Sepsis Drug Against New Coronavirus The Wire Science Retrieved 28 April 2020 Chakrabarti Ganguly 29 April 2021 Is there a way to tame the Covid virus businessline Retrieved 30 April 2021 Sepsivac A First In The World Innovation for Sepsis Management Cadila Pharma Koshy J 2020 04 21 Coronavirus Drug for sepsis to be tested for COVID 19 The Hindu ISSN 0971 751X Retrieved 28 April 2020 Paliath S 22 April 2020 Gram negative sepsis drug to be trialled for treating critically ill COVID 19 patients www indiaspend com Retrieved 28 April 2020 Sepsivac to be tested for COVID 19 treatment The New Indian Express 24 April 2020 Retrieved 28 April 2020 Ray K 23 April 2020 50 yr old bacteria drug makes a comeback in fight against coronavirus Deccan Herald Retrieved 28 April 2020 nbsp This article about the COVID 19 pandemic is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Sepsivac amp oldid 1148176960, wikipedia, wiki, book, books, library,
